146.29 +0.04 (0.02%)
After hours: 4:40PM EDT
|Bid||146.88 x 800|
|Ask||147.04 x 900|
|Day's Range||146.18 - 148.67|
|52 Week Range||99.14 - 154.09|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||41.08|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||1.36 (0.92%)|
|1y Target Est||152.40|
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Every investor in STERIS plc (NYSE:STE) should be aware of the most powerful shareholder groups. Generally speaking...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Could STERIS plc (NYSE:STE) be an attractive dividend share to own for the long haul? Investors are often drawn to...
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Steris plc NYSE:STEView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for STE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.13 billion over the last one-month into ETFs that hold STE are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
President & CEO of Steris Ltd (NYSE:STE) Walter M Rosebrough Jr sold 119,000 shares of STE on 05/31/2019 at an average price of $132.56 a share.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
The healthcare company delivered solid growth in Q4 and beat Wall Street estimates on both the top and bottom lines.
Steris (STE) delivered earnings and revenue surprises of 6.25% and 4.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Derby, Britain-based company said it had profit of $1.27. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results topped Wall Street expectations. The ...
Dublin, Ireland, May 13, 2019 (GLOBE NEWSWIRE) -- - STERIS plc (STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2019 fourth quarter ended March 31, 2019. Revenue as reported for the quarter increased 7% to $768.2 million compared with $716.0 million in the fourth quarter of fiscal 2018, with growth across all segments. Constant currency organic revenue (see Non-GAAP Financial Measures) growth was 9% for the fourth quarter of fiscal 2019.
Continued execution of consumer and medical strategies, launch of new products and strong international footprint are likely to aid Aurora Cannabis (ACB) in Q3.
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.